Markus Peck‐Radosavljevic

Author

Also Known As

M J Radosavljevic, M Milanovic, M PECKRADOSAVLJEVIC, M Peck-Radosavljevic, M Radosavljevic, M. Homoncik, M. PECK‐RADOSAVLJEVIC, M. Peck-Radosavljevic, M. Peck‐Radosavljevic, M. Radosavljevic

765

Publications

26.1K

Citations

H-Index

164

Concepts

All Affiliations

Medical University of Vienna Klinikum Klagenfurt University of Vienna Medizinische Hochschule Hannover Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

About

Markus Peck‐Radosavljevic is an author at Medical University of Vienna specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	85	8.6K
2	Health Sciences	21	27	2.3K
3	Public Health	5	5	197
4	Engineering	3	3	284
5	Natural Sciences	2	2	65

Markus Peck‐Radosavljevic

220

Publications

19.5K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Nature	2021	1.2K
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Andrew X. Zhu, Masatoshi Kudo, Eric Assénat, JAMA	2014	564
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial Michael P. Manns, Didier Samuel, Edward Gane, The Lancet Infectious Diseases HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2016	442
Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation Guobin He, Guann‐Yi Yu, Vladislav Temkin, Cancer Cell InflammationCancer ResearchReductive StressRedox SignalingJak-stat Signaling Pathway	2010	425
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma Jens Ricke, Heinz‐Josef Klümpen, Holger Amthauer, Journal of Hepatology Surgical OncologyHepatologyRadiation TherapyMedicineLiver Cancer	2019	376
Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis Mattias Mandorfer, Simona Bota, Philipp Schwabl, Gastroenterology HepatologyLiver PhysiologyHepatorenal SyndromeImmunologyGastroenterology	2014	369
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic, The Lancet Oncology Second-line TreatmentHepatologyMedicinePharmacologyPharmacotherapy	2018	340
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma Wolfgang Sieghart, Florian Hucke, Matthias Pinter, Hepatology	2013	333

Page 1